CLINICAL ANALYTICS &
DECISION SCIENCE (CADS) LAB
About Us
Data Drives Decisions
Established in 2020, Clinical Analytics and Decision Science (CADS) lab is located in Charleston and reflects the diverse energy of the area. Here at CADS lab, we offer a comprehensive environment conducive to high-impact research. Our team encompasses a broad range of disease area expertise, methodological skill sets, and a track record of publications in prestigious medical journals. Since its inception, the lab has been highly invested in solving complex real-world issues using state-of-the-art healthcare data analytics in combination with clinical decision science. In line with MUSC's "We are changing what's possible", we strive for excellence in research, provide training opportunities for next generation of scientists, and offer engaging courses in data analytics and decision science.
Research domains
Data analytics
Decision Science/
Simulation modeling
Recognition I NCI
Recent JAMA Network Open article "Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States" featured in the National Cancer Institute's Cancer Current Blog "Despite proven safety of HPV vaccines, more parents have safety concerns"
October 22, 2021
Recognition I SMDM
CADS Lab postdoctoral fellow, Dr. Chi-Fang Wu was
a Finalist for the prestigious Lee Lusted Award by
the Society for
Medical Decision
Making
The study projected the economic burden of HIV/AIDS epidemic in the USA during 2020-2035 considering variation in infection rates and inflation
October 15, 2021
Latest
News
Dr. Sonawane received a career development award from the National Institute on Minority and Disparities to study disparities in the HPV vaccination uptake and completion among low-income adolescents
September 1, 2021
News
New $4 million grant to determine optimal anal cancer screening among women with lower genital tract precancerous or cancer
Dr. Deshmukh and colleagues (Dr. Keith Sigel [Mt. Sinai] and Dr. Elizabeth Chiao [MD Anderson Cancer Center]) received a grant from NCI to determine effective and cost-effective screening strategies for anal cancer prevention among high-risk women with a history cervical, vaginal, or vulvar cancer or precancerous
September 1, 2021
News
